Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial
Primary result · CINResult — go to the resultOdds ratio 0.21 95% CI 0.13–0.34Authors' conclusion
In patients at risk of renal injury undergoing coronary angiography for ACS, a short (5 day) course of once-daily inorganic nitrate reduced CIN, improved kidney outcomes at 3 months, and MACE events at 1 year compared to placebo.
Study context
- Population
- At-risk patients with acute coronary syndromes (ACS) undergoing coronary angiographymedian follow-up 1.0 years
- Participants
- 640 patients
- Comparison
- Inorganic nitrate vs placebo
- Inorganic nitraten = 319
- Placebon = 321reference
- Primary endpoint
- Contrast-induced nephropathy (KDIGO criteria)
Methodological detailsdouble-blind, placebo-controlled, single-centre
- Double-blind
- Placebo-controlled
- Single-centre
Primary result
Contrast-induced nephropathy (CIN)
Odds ratio
0.21
95% CI 0.13–0.34
P < 0.001
By group
Inorganic nitratevs Placebo
OR 0.21 (95% CI 0.13–0.34); P < 0.001
As reported in the abstract
Secondary outcomes
Procedural MI
P = 0.003
| Outcome | Between-group change in eGFR (95% CI) | |
|---|---|---|
| Change in eGFR · 3 months | 5.17 (2.94–7.39) | |
| −50510Difference (linear scale) |
| Outcome | Inorganic nitrate | Placebo | P value |
|---|---|---|---|
| MACE · 1 year | — not stated in the abstract | 18.1% | P = 0.001 |
— not stated in the abstract
Original publication
Inorganic nitrate benefits contrast-induced nephropathy after coronary angiography for acute coronary syndromes: the NITRATE-CIN trial. Eur Heart J. Published 21 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →